Sakar Healthcare Limited (NSE: SAKAR) delivered an impressive quarter with significant revenue growth of 53% and EBITDA growth of 114% year-on-year for Q2 FY27. The company’s robust performance is driven by its oncology division, which saw substantial progress in regulatory approvals and technology transfers.

Financial Highlights

The financial results for Q2 FY27 reflect the company’s strong operational performance. The gross profit stood at ₹4,168.05 lakhs, up 53% YoY, while the operating EBITDA reached ₹2,434.53 lakhs, marking a 114% increase. The profit after tax (PAT) surged to ₹1,130.69 lakhs, up 149% YoY.

Strategic Developments

Sakar Healthcare’s strategic initiatives have paid off, with 69 oncology product contracts executed and 45 commercial discussions underway. The company has also shared 351 dossiers globally, of which 191 have been submitted to regulatory agencies, and 22 marketing authorizations (MAs) have been granted. The approved MAs are well dispersed globally, including 11 in Europe & UK, 6 in Latin America, 4 in APAC, and 1 in Canada.

Looking Ahead

Mr. Sanjay Shah, Managing Director, commented on the results, stating, “Q2 FY27 has been a quarter of meaningful progress for our oncology business, with encouraging developments across regulatory approvals, technology transfers, and global market access. These milestones have strengthened our international presence, deepened relationships with global partners, and laid a strong foundation for future growth.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sakar Healthcare Limited

Sakar Healthcare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sakar posts a 9.6% three-month gain, but softens in the last few weeks. The PEG reaches 3.04. The stock trades on brand and index weight, not on growth. Revenue grows at 22.0% and profits at 23.0% CAGR. Both numbers are exceptional. The stock gives back 13.0% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 22.0% and profits at 23.0%, with D/E of 0.30. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 3.04 premium is usually justified. Check Fundamentals of Sakar Healthcare Limited.

Sudeep Pharma Limited (NSE: SUDEEPPHRM) has received approval from the Gujarat Food and Drug Control Administration (FDA) for its new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat, authorising the commencement of manufacturing operations at the site. This approval marks a significant milestone in the company’s growth journey and confirms that the facility’s manufacturing systems, quality controls, and compliance framework meet the requirements for commencing operations.

Strengthening Manufacturing Capabilities

The facility has an annual installed capacity of 51,200 MT, significantly strengthening the company’s manufacturing capabilities across Pharma, Food & Nutrition, and Specialty Ingredients. This approval allows the company to bring the new capacity on stream and serve growing demand from pharmaceutical, food, and nutrition customers in domestic and international markets.

Facility’s Role in Growth Strategy

Commercial supplies from this facility are expected to commence in H2 FY27, following the completion of customer qualification processes. Approximately 60% of the facility’s capacity is allocated to the company’s existing Pharma, Food & Nutrition portfolio, while the remaining capacity will cater to newer product categories, including phosphates, glycinates, gluconates, and citrates. The facility will also provide dedicated capacity for higher-value ingredients, reinforcing the company’s focus on portfolio diversification and strengthening its presence in regulated markets.

Mr. Sujit Bhayani, Managing Director, Sudeep Pharma Limited, commented on the development, stating: ‘The FDA approval for our 179 Nandesari greenfield facility marks an important milestone in our growth journey, enabling us to commence manufacturing operations and unlock significant additional capacity. It strengthens our ability to serve a wider customer base across pharmaceutical, food, and nutrition segments in India and international markets. With the approval in place, we can now accelerate customer qualification processes and audits at the facility, facilitating the onboarding of both new and existing customers. The facility also provides us with the flexibility to expand our presence across existing and newer product categories, including high-value, specialised ingredients such as bisglycinates. This will enable us to address evolving customer requirements, scale up our specialised ingredients portfolio, and pursue larger opportunities in international markets. We believe this investment will serve as an important growth driver as we progress into the next phase of our journey.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sudeep Pharma Limited

Sudeep Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Sudeep posts a 16.0% three-month gain, but softens in the last few weeks. Industry-leading margins of 27.0% reflect exceptional pricing power and operational efficiency. Revenue grows at 14.4% and profits at 40.5% CAGR. The market consistently rewards this kind of compounding. The stock gives back 9.6% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 14.4% and profits at 40.5%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Sudeep Pharma Limited.

Orchid Pharma Limited (ORCHPHARMA) has announced its strategic expansion into Latin America through a licensing and supply agreement with Laboratorio Libra S.A. (Libra). This partnership will cover the commercialization of Exblifep® (cefepime/enmetazobactam) across nine Latin American markets, including Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, and Uruguay. Exblifep is a novel antibiotic combination indicated for complicated urinary tract infections and hospital-acquired and ventilator-associated bacterial pneumonia caused by Gram-negative pathogens.

Strategic Partnership

Libra receives exclusive rights to register, import, and market Exblifep in these countries, while Orchid Pharma manufactures and supplies the finished dosage form. The collaboration aims to provide clinicians in the region with a new option for treating serious Gram-negative hospital infections, addressing the growing challenge of antimicrobial resistance.

Market Potential

Over the first 10 years, the partnership is expected to represent a potential commercial opportunity of approximately USD 80 million, based on projected demand across these markets. The agreement underscores Orchid Pharma’s commitment to expanding its footprint in the Latin American pharmaceutical market, leveraging Libra’s established presence and expertise in the region.

Manish Dhanuka, Managing Director of Orchid Pharma Limited, stated, ‘Extending Exblifep into Latin America is a priority for Orchid, and Libra is well placed to lead its introduction across these markets. Together, we aim to give clinicians in the region a new option for treating serious Gram-negative hospital infections.’ Carlos Scherschener, CEO of Laboratorio Libra S.A., added, ‘We are honored to partner with Orchid Pharma to bring Exblifep to Latin America, expanding access to an innovative therapeutic option for patients across the region while contributing to the response to the growing challenge of antimicrobial resistance.’

This expansion marks a significant milestone for Orchid Pharma as it continues to innovate and expand its global footprint in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Orchid Pharma Limited

Orchid Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Orchid falls 12.5% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. No meaningful dividend — total return is entirely dependent on capital appreciation. The stock holds at 65% of its 52-week range with RSI at 36. In other words, neither side has a clear edge right now. The stock rises -12.5% in three months on 22.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Orchid Pharma Limited.